Hikma Set For Ryaltris Take Off As Glenmark Wins USFDA Nod

Companies Partnered Up In March 2020; Ryaltris Already Rolled-Out In Europe

Glenmark is celebrating a “major milestone,” after its Ryaltris nasal spray to treat seasonal allergic rhinitis was approved by the FDA. Hikma will handle commercialization in the US, as part of its continued specialty push in the market.

Nasal_Spray
Hikma has described Ryaltris as "very interesting" • Source: Shutterstock

Hikma Pharmaceuticals’s commercialization agreement with Glenmark Pharmaceuticals in the US covering rights for the Indian firm’s Ryaltris (olopatadine hydrochloride/mometasone furoate) 665mcg/25mcg nasal spray is set to bear fruit two years after the deal was signed, following US Food and Drug Administration approval for the seasonal allergic rhinitis treatment.

Glenmark has lauded a “major milestone,” noting that its approval for the 505(b)(2) hybrid new drug application product “clearly supports our efforts to bring

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Products

More from Generics Bulletin